Pre-market 06 Feb 2026: INFE.PA Compagnie Industrielle et Financière d’Entreprises SA EURONEXT €71.00 oversold bounce: possible rebound near €65.85

The INFE.PA stock opens pre-market on 06 Feb 2026 at €71.00, signalling a potential oversold bounce after a 3-month drop of -14.46%. Traders should note thin liquidity with volume 16 and average volume 85, which increases volatility risk on rebounds. We outline a tactical bounce plan, support and resistance levels, valuation checks, and a Meyka AI forecast to frame short-term trade ideas.

INFE.PA stock quick snapshot

Compagnie Industrielle et Financière d’Entreprises SA (INFE.PA) trades on EURONEXT in Europe at €71.00. Market cap is €83,492,663.00 and shares outstanding are 1,175,953.00. Year high is €100.00 and year low is €50.50, giving a clear recent trading range for mean reversion setups.

Why this is an oversold bounce setup

Price sits below the 50-day average €75.04 but above the 200-day average €65.85, a classic bounce zone for mean reversion trades. The 3-month change is -14.46%, indicating recent selling pressure that can trigger short-term rebounds. Low daily volume increases gap risk, so position sizing and tight stops matter.

Fundamentals and valuation check for INFE.PA stock

INFE.PA shows EPS €6.35 and a trailing PE of 11.18, below the Industrials sector average PE 25.48, suggesting value relative to peers. Book value per share is €23.84, cash per share €29.94, and dividend per share €11.33, implying a dividend yield of 15.96% at current price. Payout ratio is 0.20, which supports dividend sustainability but warrants verification of one-off distributions.

Technical levels, targets and a trading plan

Immediate support cluster sits near the 200-day average €65.85 and the recent swing low €50.50 acts as a deeper stop reference. Short-term resistance appears at the 50-day average €75.04 and the 3-month moving congestion near €80.00. A conservative bounce trade: buy on weakness toward €66.00–€66.50, target €75.00 and stop €64.00. Position size should reflect low liquidity (volume 16.00).

Meyka AI grade, forecast and price targets

Meyka AI rates INFE.PA with a score out of 100: 69.79 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 1-year price of €74.29, a 3-year target of €83.65, and a 5-year target of €93.19. Compared with the current €71.00, the 1-year model implies an upside of 4.63%, but forecasts are model-based projections and not guarantees. For more live metrics see our Meyka INFE.PA page: Meyka INFE.PA page.

Risks and potential catalysts for INFE.PA stock

Key risks include very low trading volume, project execution risk in construction, and concentrated ownership as a subsidiary of Alfred de Musset SAS. Catalysts that could trigger a stronger rebound include better-than-expected contract awards, a confirmed dividend policy update, or sector strength in Industrials, which has YTD performance 1.81%. Monitor liquidity and news flow closely before scaling positions.

Final Thoughts

INFE.PA stock presents a defined oversold bounce opportunity in the pre-market on 06 Feb 2026 at €71.00. Valuation looks attractive with a trailing PE of 11.18 and cash per share €29.94, while the 200-day average €65.85 offers a logical support zone for staged entries. Our suggested tactical plan targets €75.00 on a rebound with a stop near €64.00, reflecting low liquidity (volume 16.00) and execution risk. Meyka AI’s 1-year forecast of €74.29 implies a 4.63% upside from current levels; remember forecasts are model-based projections and not guarantees. Use position sizing and watch earnings, contract awards, and dividend notices as catalysts before committing capital.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.